Although progress has been made through early detection by means of prostate-specific antigen (PSA) screening and therapeutic interventions, around 10% of patients develop metastatic disease, leading to a higher chance of PCa-related death [2,3]. Here, KLK3 is linked to metastatic neoplasm.